

# Resource Summary Report

Generated by [nidm-terms](#) on Aug 11, 2026

## Phospho-Histone H2A.X (Ser139) antibody

RRID:AB\_3670974

Type: Antibody

### Proper Citation

Proteintech Cat# 83307-2-RR, RRID:AB\_3670974

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_3670974](http://antibodyregistry.org/AB_3670974)

**Proper Citation:** Proteintech Cat# 83307-2-RR, RRID:AB\_3670974

**Target Antigen:** Phospho-Histone H2A.X (Ser139)

**Host Organism:** Rabbit

**Clonality:** recombinant

**Comments:** Applications: WB, IHC, IF/ICC, ELISA

**Antibody Name:** Phospho-Histone H2A.X (Ser139) antibody

**Description:** This recombinant targets Phospho-Histone H2A.X (Ser139)

**Target Organism:** human

**Clone ID:** clone 5N19

**Antibody ID:** AB\_3670974

**Vendor:** Proteintech

**Catalog Number:** 83307-2-RR

**Record Creation Time:** 20250819T222452+0000

**Record Last Update:** 20250820T020725+0000

### Ratings and Alerts

No rating or validation information has been found for Phospho-Histone H2A.X (Ser139) antibody.

No alerts have been found for Phospho-Histone H2A.X (Ser139) antibody.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 3 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [nidm-terms](#) .

Zhang H, et al. (2026) Lactate-driven H3K18 lactylation promotes cisplatin resistance in bladder cancer via HNRNPF-Parkin mediated mitophagy. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 88, 101435.

Ye H, et al. (2026) Targeting ATF4 overcomes dual resistance to chemo-immunotherapy in gastric cancer by disrupting the DNA damage response. Journal for immunotherapy of cancer, 14(6).

Tian C, et al. (2026) PATZ1 condensation adjacent to PML nuclear bodies suppresses HBoV transcription as an intrinsic antiviral defense. Cell reports, 45(6), 117437.